Efficacy of pharmacotherapies for short-term smoking abstinance: A systematic review and meta-analysis

1477-7517-6-25 1477-7517 Research Efficacy of pharmacotherapies for short-term smoking abstinance: A systematic review and meta-analysis Mills J Edward emills@sfu.ca Wu Ping pwu@ccnm.edu Spurden Dean Dean.Spurden@Pfizer.com Ebbert O Jon jon.ebert@mayo.edu Wilson Kumanan kwilson@ohri.ca

Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

Department of Epidemiology, LSHTM, UK

Pfizer Limited, Tadworth, UK

Mayo Clinic College of Medicine, Rochester, USA

Department of Medicine, Ottawa Hospital Research Institute, Ottawa, Canada

Harm Reduction Journal 1477-7517 2009 6 1 25 http://www.harmreductionjournal.com/content/6/1/25 19761618 10.1186/1477-7517-6-25 3 2 2009 18 9 2009 18 9 2009 2009 Mills et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Smoking cessation has important immediate health benefits. The comparative short-term effectiveness of smoking cessation interventions is not well known. We aimed to determine the relative effectiveness of nicotine replacement therapy (NRT), bupropion and varenicline at 4 weeks post-target quit date.

Methods

We searched 10 electronic medical databases (inception to October 2008). We selected randomized clinical trials [RCTs] evaluating interventions for our primary outcome of abstinence from smoking at at-least 4 weeks post-target quit date, with biochemical confirmation. We conducted random-effects odds ratio (OR) meta-analysis and meta-regression. We compared treatment effects across interventions using head-to-head trials and calculated indirect comparisons.

Results

We combined a total of 101 trials evaluating delivery of NRT versus inert controls at approximately 4 weeks post-target quit date (total n = 31,321). The pooled overall OR is OR 2.05 (95% Confidence Interval [CI], 1.89-2.23, P =< 0.0001). We pooled data from 31 bupropion trials contributing a total n of 11,118 participants and found a pooled OR of 2.25 (95% CI, 1.94-2.62, P =< 0.0001). We evaluated 9 varenicline trials compared to placebo. Our pooled estimate for cessation at 4 weeks post-target quit date found a pooled OR of 3.16 (95% CI, 2.55-3.91, P =< 0.0001). Two trials evaluated head to head comparisons of varenicline and bupropion and found a pooled estimate of OR 1.86 (95% CI, 1.49-2.33, P =< 0.0001 at 4 weeks post-target quit date. Indirect comparisons were: NRT and bupropion, OR, 1.09, 95% CI, 0.93-1.31, P = 0.28; varenicline and NRT, OR 1.56, 95% CI, 1.23-1.96, P = 0.0002; and, varenicline and bupropion, OR 1.40, 95% CI, 1.08-1.85, P = 0.01.

Conclusion

Pharmacotherapeutic interventions are effective for increasing smoking abstinence rates in the short-term.

Introduction

Smoking remains the leading cause of preventable death in the world.1 Smoking cessation is associated with important benefits at the individual and societal levels. Given the prevalence of smoking, considerable efforts have been directed toward developing interventions to assist smokers in quitting. However, smoking cessation interventions have had heterogeneous successes.2 Smoking cessation is necessary to reduce future morbidity and mortality, however many patients have difficulty discontinuing.

Both psychosocial and pharmaceutical interventions have been evaluated for their success in achieving smoking discontinuation.34 Drug therapies are now licensed in North America and Europe to promote smoking cessation. The most commonly evaluated of these has been nicotine replacement therapy [NRT].56 More recently, attention has focused on the use of anti-depressant therapy and specifically the agent bupropion7. A new intervention approved in 2006, varenicline, targets nicotine receptors to reduce craving and pleasure sensations. Recent guidelines and evaluations call for combining therapies to provide optimal patient management.38

We,.9 and others,. 10111213 have previously reported on the efficacy of these interventions for longer-term cessation (3-12 months) durations. No systematic review has yet evaluated short-term quit rates from available therapies. Guidelines for smoking cessation programmes consider quitting 4-weeks post-planned quit date as a successful short-term cessation.14 Short-term smoking abstinence is especially important in patients requiring immediate behaviour changes, such as those with recent cardiovascular events.15 or undergoing surgery.16 We conducted a meta-analysis of Randomized Clinical Trials [RCTs] to identify the effectiveness of the various pharmacological interventions in improving abstinence rates at 4-weeks and 6 months.

Methods

Eligibility Criteria

Our primary outcome of interest was smoking abstinence at approximately 4 weeks post-target quit date (TQD). Our secondary outcomes were short-term smoking abstinence defined as 6 months after initiating treatment or closest available data to that time point, within one month. We included any RCT of NRT of any delivery method, bupropion or varenicline. We included only RCTs of at least 4 weeks duration with biochemical confirmation of smoking abstinence because of the likelihood of abstinence over-reporting. While methods of assessing smoking abstinence vary from study to study, the most common method is self-report. However, this can have false cessation rates as high as 30%.17False reporting is most likely to occur in a trial setting or in assessing smoking status after a medical event. Laboratory tests are often used to verify smoking status, especially in clinical trials. Methods of biological verification include serum and saliva thiocyanate (SCN), expired carbon monoxide (CO), plasma, saliva and urinary cotinine and plasma and urinary nicotine. Each of these have various strengths and weaknesses.18 Studies had to report smoking abstinence as either sustained abstinence at the time periods or point-prevalence of abstinence. When both outcomes were available, we considered sustained abstinence to be a superior clinical marker of abstinence. We excluded dose ranging studies, non-RCTs, post-hoc analyses, maintenance therapy, and studies that reported outcomes as self-report.

Study endpoints

Our primary endpoint was the 4-week post-TQD. This is variably reported in studies over years of publications. National committees require data on the 4-week post-TQD and each group of trials of intervention deals with this endpoint differently. Newer studies typically report this as the last 4-weeks of treatment as pharmacotherapy is begun prior to TQD. Where this specific endpoint is reported, we extracted data on 4-week post-TQD. Where not reported, we extracted data on 4 weeks post-intervention. Our secondary endpoint, 6-months post intervention is typically reported as 6 months post-treatment, but may also be reported as 6 months post TQD. Where reported specifically, we extracted data on 6-month post-TQD.

Search strategy

In consultation with a medical librarian (PR), we established a search strategy. We searched independently, in duplicate, the following 10 databases (from inception to October 1, 2008): MEDLINE, EMBASE, Cochrane CENTRAL, AMED, CINAHL, TOXNET, Development and Reproductive Toxicology, Hazardous Substances Databank, Psych-info and Web of Science, databases that included the full text of journals (OVID, ScienceDirect, and Ingenta, including articles in full text from approximately 1700 journals since 1993). In addition, we searched the bibliographies of published systematic reviews.519202122232425710111326 and health technology assessments.27 Searches were not limited by language, sex or age.

Study selection

Two investigators (EM, PW) working independently, in duplicate, scanned all abstracts and obtained the full text reports of records, that indicated or suggested that the study was a RCT evaluating a smoking abstinence therapy on the outcomes of interest. After obtaining full reports of the candidate trials (either in full peer-reviewed publication or press article) the same reviewers independently assessed eligibility from full text papers.

Data collection

Two reviewers (PW, EM) conducted data extraction independently using a standardized pre-piloted form. Reviewers collected information about the smoking intervention tested, the population studied (age, sex, underlying conditions), treatment dosages and dosing schedules, the treatment effect at 4 weeks post-TQD and at 6 months post-intervention, the specific measurement of abstinence (sustained or point-prevalence), and the chemical confirmation methods. Study evaluation included general methodological quality features including allocation concealment, sequence generation, blinding status, intention-to-treat, and appropriate descriptions of loss to follow-up. We entered the data into an electronic database such that duplicate entries existed for each study; when the two entries did not match, we resolved differences through discussion and consensus.

Data analysis

In order to assess inter-rater reliability on inclusion of articles, we calculated the Phi statistic, which provides a measure of inter-observer agreement independent of chance.28 We calculated the Odds Ratios [OR] and appropriate 95% Confidence Intervals [CIs] of outcomes according to the number of events of abstinence reported in the original studies or sub-studies. Odds Ratios are the preferred effect measure in smoking cessation trials. In circumstances of zero outcome events in one arm of a trial, we added 1 to each arm, as suggested by Sheehe.29 We first pooled studies of all NRT interventions versus all controls using the DerSimonian-Laird random effects method,.30 which recognizes and anchors studies as a sample of all potential studies, and incorporates an additional between-study component to the estimate of variability.31 We calculated the I²statistic for each analysis as a measure of the proportion of the overall variation that is attributable to between-study heterogeneity.32 Forest plots are displayed for each primary analysis, showing individual study effect measures with 95% CIs, and the overall DerSimmonian-Laird pooled estimate. We then conducted a meta-regression analysis on the NRT studies with predictors of heterogeneity including the following covariates: placebo control; reporting of sequence generation; reporting of allocation concealment; use of gum or patch; and, method of chemical confirmation of abstinence. We additionally conducted separate pooled analyses of NRT versus placebo, gum versus control and patch versus control. We conducted all analyses at 4 weeks and also at 6 months post-TQD. For bupropion trials, we pooled all bupropion trials versus all controls and conducted a meta-regression analysis using the following covariates: placebo control; reporting of sequence generation; reporting of allocation concealment; method of chemical confirmation of abstinence; and plans to quit. We conducted separate meta-regression analyses and calculated the relevant ORs for the covariates as the exponent of the coefficient.33 We additionally pooled all placebo-controlled trials and evaluated effect sizes at 4 weeks and at 6 months post-TQD. For head-to-head trials of bupropion versus NRT, we conducted pooled random-effects analyses at 4 weeks and at 6 months post-TQD. For varenicline trials, we conducted pooled random-effects analyses of varenicline versus placebo and for head-to-head trials of varenicline versus bupropion or NRT at 4 weeks year and at 6 months. post-TQD. Head-to-head trials provide the strongest inferences regarding intervention superiority.34 However, with so few head-to-head trials of varenicline versus NRT, we conducted indirect comparisons of these interventions versus placebo using methods described by Bucher et al.35 This method maintains the randomization from each trial and compares the summary estimates of pooled interventions with CIs. Analyses were conducted using StatsDirect (version 2.5.2, http://www.statsdirect.com) and Comprehensive Meta-analysis (version 2, http://www.meta-analysis.com).

Results

Study inclusion

We identified 795 abstracts from our extensive searches. We excluded 532 as irrelevant to meeting our inclusion criteria. We obtained 263 full-text studies for screening. We further excluded 94 studies for reasons explained in figure 1 [See Additional File 1]. In total, we included data from 168 RCTs. Agreement was near perfect (φ => 0.9).

Additional file 1

Characteristics of included studies. Supplementary Tables addressing study populations and interventions.

Click here for file

Figure 1

Flow diagram of included studies

Flow diagram of included studies.

Methods reporting

Nicotine Replacement Therapy

One hundred and fifteen RCTs of NRT provided either safety or efficacy data at approximately 4 weeks post-TQD. 36373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150. Eighty-two (82/115) used a placebo control 36373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116150. Trials were variably reported with only 43 reporting methods of sequence generation3739414652555770737475768083858687888990919295969798103105110111112114115116118121125126139142144145148. Eighteen (18/115) reported on allocation concealment. 37394146707681848688899095105111112126148, 81 (81/115) reported on who was blinded36373839404142434445464748495051525354555657585960616263646566676869707172737576777812013113279808182838485868788899091929394969798149100101102103105106107108109110111112113114115116. Most trials used some form of chemical confirmation of abstinence, with carbon monoxide being the most common (104/115).3637384041424344454647484950515253545556575960616263646566676869707173117118119120122123124129130131132133134.727475767778798081838485868788899091929394979899135137138139140149100101102103104105106107108109110111113114115116141142143144145146147148, salivary cotinine (26/115).42454650566668757679839395103106111123125128129132133134145147150, serum status (7/115).39435871114119136, or urine sampling (4/115)74112126129. Most (94/115) reported that participants were trying to quit smoking.3637383941444546474849505152545556575859606162636465117118121122124125126127128129131132686970717273747577788081828586878990919394979899100102103104105106108110111112113114115116136137138139140143144145146147148149.

Bupropion

Forty-two bupropion trials met our inclusion criteria.113114142143149151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187 and reported on outcomes at 4 weeks post-TQD. Almost all trials (40/42) used a placebo control.113114149151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187, with 2 providing education.143 and counseling.142 as controls. The quality of reporting studies varied considerably. We found that important study quality indicators were reported sporadically. Sequence generation was reported in 23 of 42 trials.113114142152153154157158159161162163164169170171172173176180182185186, allocation concealment was reported in 12 of 42 trials.152153157158159162163164170176182186, the status of who was blinded was reported in 38 of 42 trials.113114142149151152153154155156157158159160161162163164165166167168169170171172173174176177180181182183184185186187, 37 trials.113114142143149151152153154155157158159160161162163164165167168169170171172174175176177180181182183184185186187 confirmed cessation using carbon monoxide testing, while 13 used urinary cotinine114152153157158159166173174178179180184. Almost all trials used participants that were planning to quit smoking (38/42).113114142143149151152153154155156157158159160161163165166167168169170171173174175176177178179180182183184185186187.

Varenicline

Eleven varenicline studies met our inclusion criteria162163164188189190191192193194195. One reported only on safety193. All trials had a placebo control, 3 also had a bupropion control in their 3 armed trials163164188. We found that almost all (7/11) provided an additional intervention of counseling available162163164190191192194. Sequence generation was reported in 6 of 11 studies.162163164189192195, allocation concealment in 7 of 11 studies.162163164189192194195, blinding status in all studies (11/11), and the use of carbon monoxide testing in 10 of 11 studies.162163164188189190191192194195, and urinary cotinine in 1 of 11 studies193. Five trials reported that the participants were trying to stop smoking163189190192195.

Effectiveness

Nicotine Replacement Therapy

We combined a total of 101 trials.363738394041424345464749505152545556575859606162636465117118119121123128129130131132147.666768697173747576777879808182848687888990134135137138149919495979899100103105106111114115116139140141142143144145146evaluating some delivery form of NRT versus inert controls at approximately 4 weeks post-TQD (total n = 31,321). The pooled overall OR is OR 2.05 (95% CI, 1.89-2.23, P =< 0.0001, I²= 51.8%, 95% CI = 38% to 61.3%, P =< 0.0001, See Figure 2). This assessment permitted a sufficient number of studies to assess publication bias and we found marginal evidence of it (Egger's P = 0.055, See Figure 3). We evaluated whether reporting exactly 4 week post-TQD data influenced outcomes and found trials reporting exactly 4 week post-TQD data were more likely to report treatment effects (OR 2.11, 95% CI, 1.97-2.27, P =< 0.0001). These pooled trials yielded an OR 1.82, 95% CI, 1.62-2.05, P =< 0.0001, I²= 41.6%, 95% CI, 9.1 to 59.1%, P = 0.002). Trials reporting on sustained abstinence at approximately 4 weeks post-TQD yielded a similar pooled estimate (38 RCTs.455254565760616667697375818286878991949899103116124129131139142145149, n = 17,606, OR 2.24, 95% CI, 1.94-2.28, P =< 0.0001, I²= 67.7%, 95% CI = 53.7% to 76.1%, P =< 0.0001). When we evaluated trials assessing NRT only to placebo we pooled 74 trials.3637383940414243454647495051525455565758596061626364656667686971737475767778798081821318486878889909194959798100103105106111114115116149 (total n = 25,154: 24,654) and found a pooled estimate of 2.13 (95% CI, 1.94-2.34, P =< 0.0001, I²= 53.6%, 95% CI = 37.6% to 64%, P =< 0.0001, this was not dissimilar when evaluating sustained abstinence (29 RCTs.455254565760616667697375818286878991949899103124131149, n = 14,306, OR 2.36 (95% CI, 2.04-2.73 I²= 61.4%, 95% CI = 37.5% to 73.5%, P =< 0.0001).

Figure 2

Random effects meta-analysis of all NRT trials combined versus all inert controls at 4 weeks

Random effects meta-analysis of all NRT trials combined versus all inert controls at 4 weeks. post-TQD.

Figure 3

Funnel plot evaluating publication bias in NRT versus control event rates at 4 weeks post-TQD

Funnel plot evaluating publication bias in NRT versus control event rates at 4 weeks post-TQD.

When we specifically looked at the effectiveness of NRT gum versus all inert controls we pooled data from 41 trials.3637383940414245464750677478106111114117118119121123124128129130131132134137138141144146 (n = 9,460) and found an OR of 1.76 (95% CI, 1.54-2.01, P =< 0.0001, I²= 38.9% (95% CI = 3.8% to 57.6%, P = 0.004). This was not dissimilar from gum versus placebo controls (23 trials.3637383940414245464750677478106111114124131, n = 5818, OR 1.66, 95% CI, 1.41-1.96, P =< 0.0001, I²= 41.1% P = 95% CI = 0% to 63.2%, P = 0.01). When we specifically examined trials assessing the effectiveness of NRT cutaneous patches versus inert controls we included data from 47 RCTs.495152545658596062636465666971737779828486878990919597100103105106115135139141142143144145149 (n = 15,980) and found a pooled estimate of 2.11 (95% CI, 1.85-2.40, P =< 0.0001, I²= 54.8%, 95% CI, 34.7 to 66.7%, P =< 0.0001). This was not different when examining NRT patches versus placebo controls (38 trials 495152545658596062636465666971737779828486878990919597100103105106115149, n = 14,988, OR 2.15, 95% CI, 1.86-2.48, P =< 0.0001, I²= 59.5%, 95% CI = 39.3 to 70.8%, P =< 0.0001).

When evaluating NRT versus controls at 6 months (96 RCTs, n = 30,422) we found a pooled estimate of OR 1.92 (95% CI, 1.73-2.14, P =< 0.0001, I²= 64.2%, 95% CI, 54.8 to 70.8%, P =< 0.0001). This was not dissimilar when evaluating NRT as either gum (23 RCTs, n = 5818, OR 1.69, 95% CI, 1.37-2.08, P =< 0.0001, I²= 55.9%, 95% CI, 21.8 to 71.3%, P = 0.0004) or cutaneous patch (43 RCTs, n = 16,298, OR, 1.90, 95% CI, 1.62-2.33, I²= 62.4%, 95% CI, 45.5 to 72.3%, P =< 0.0001).

Bupropion

We pooled data from 31 trials.114142143149152153154155156157162163164165166167168169170171172173175176177182183184185186187 contributing a total n of 11,118 participants providing data at approximately 4 weeks post-TQD and found a pooled OR of 2.25 (95% CI, 1.94-2.62, P =< 0.0001, I²= 78, 95% CI, 70-83%, P =< 0.001, See Figure 4). When we evaluated studies assessing sustained cessation (25 randomized cohorts.142149151152154155159160162163164165166168170171175176180182185187, n = 8,724) we found a pooled OR of 1.96, 95% CI, 1.39-2.79, P = 0.0002, I²= 89%, 95% CI, 86-92%, P =< 0.0001, See Figure 5). We were able to explain the large heterogeneity in the analysis through meta-regression as studies failing to report allocation concealment were associated with increased effect sizes (OR 2.29, 95% CI, 2.05-2.60, P =< 0.0001), as were studies confirming abstinence through urinary cotinine (OR 2.44, 95% CI, 2.18-2.66, P =< 0.0001), but not those utilizing carbon monoxide confirmation (OR 1.30, 95% CI, 0.87-1.95, P = 0.18).

Figure 4

Random effects meta-analysis of smoking cessation with bupropion versus controls at 4-weeks post-TQD

Random effects meta-analysis of smoking cessation with bupropion versus controls at 4-weeks post-TQD.

Figure 5

Random effects meta-analysis of sustained smoking abstinence with bupropion versus controls at 4-weeks post-TQD

Random effects meta-analysis of sustained smoking abstinence with bupropion versus controls at 4-weeks post-TQD.

Our secondary outcomes for effectiveness also indicated significant benefits with bupropion over controls at 6 months (OR 1.75, 95% CI, 1.54-1.97, P =< 0.0001, I²= 32%, 95% CI, 0-53%, P =< 0.0001). This effect was consistent when applying only continuous abstinence in the 6 month period (OR 1.94, 95% CI, 1.62-2.32, P =< 0.0001, I²= 34, 95% CI, 0-62, P = 0.04).

Varenicline

When we evaluated varenicline for smoking abstinence at approximately the last 4 weeks of treatment (4 weeks post-TQD) compared to placebo, we pooled 9 trials.162163164189190191192194196 contributing a total n of 5,192 participants. Our pooled estimate for abstinence at 4 weeks post-TQD found a pooled OR of 3.16 (95% CI, 2.55-3.91, P =< 0.0001, I²= 53%, 95% CI, 0-76%, P = 0.02, See Figure 6). We were able to explain the heterogeneity in the analysis through meta-regression as studies failing to report allocation concealment were associated with increased effect sizes (OR 3.35, 95% CI, 2.45-4.57, P =< 0.0001). Our 6 month evaluations of varenicline versus placebo yielded similar estimates for continuous abstinence in the 6 month period (OR 2.17, 1.48-3.19, P =< 0.0001, I²= 80, 95% CI, 49-90%, P =< 0.0001).

Figure 6

Random effects meta-analysis of varenicline versus placebo at 4 weeks post-TQD

Random effects meta-analysis of varenicline versus placebo at 4 weeks post-TQD.

Two trials evaluated head to head comparison of varenicline and bupropion and found a pooled estimate of OR 1.86 (95% CI, 1.49-2.33, P =< 0.0001) using continuous abstinence rates at 4 weeks and, at 6 months post-TQD (OR 1.64, 95% CI, 1.28-2.10, P =< 0.0001).163164 One trial evaluated varenicline versus NRT patch (n = 757) for continuous abstinence at the last 4 weeks post-TQD using carbon monoxide confirmation (OR 1.70, 95% CI, 1.26-2.28, P =< 0.001).188 This same trial reported on continuous abstinence at 6 months (24 weeks), but the difference was not significant (OR 1.29, 95% CI, 0.94-1.77, P = 0.11).

Adjusted indirect comparison (Figure 7)

Figure 7

Indirect comparisons

Indirect comparisons.

We applied an adjusted indirect comparison evaluating NRT, bupropion and varenicline on our primary endpoint of 4 weeks post-TQD abstinence. We were unable to display a significant difference between NRT and bupropion at 4-weeks (OR, 1.09, 95% CI, 0.93-1.31, P = 0.28). Varenicline was superior to both NRT (OR 1.56, 95% CI, 1.23-1.96, P = 0.0002) and bupropion at post-TQD (OR 1.40, 95% CI, 1.08-1.85, P = 0.01).

Discussion

This study confirms the short-term effectiveness of all three smoking interventions compared to placebo. Our findings stand in line with outcomes evaluated over a longer period, up to one year, of these same interventions.910 This finding should be of interest to clinicians, policy-makers and patients. As interventions to assist in smoking cessation are increasingly available, the combination of these interventions, along with socio-behavioural interventions, should be a research priority.8

The definition of smoking abstinence and relapse are variable across studies. The most common time periods of smoking cessation required to be considered abstinent are 24 hours, 7 days and 30 days. Relapse is defined by the National Heart, Lung and Blood Institute as having smoked at least a puff for 7 days after having quit. Seventy five to 80 percent of smokers relapse within the first 6 months. Relapse rates continue to remain high from 6 to 12 months (7 to 35% of those abstinent at 6 months). Relapse occurs at a lower rate following one year of cessation.4 The National Center for Health Education Code of Practice and Standards for the Evaluation of Group Smoking Cessation Programs recommends at least one year of follow-up before determining if patients have quit smoking.4 The National Institute for Clinical Excellence (UK) Guidelines require the reporting of short-term abstinence rates. Further, immediate abstinence of smoking following a major cardiovascular event has major benefits in preventing secondary events.197 We recognize that multiple short-term abstinence attempts followed by relapses may be associated with long term smoking use, an issue that is increasingly complex to manage from a clinical and public health perspective.198 However, our findings are consistent with the longer term evaluations and indicate that sustained abstinence is possible in the clinical trial setting. Furthermore there are some physiological and health advantages to short-term abstinence. For example, individuals with cardiovascular events can immediately benefit from smoking discontinuation because of improvements in several physiological variables including reduced myocardial oxygen demand, improved myocardial oxygen supply, reduced activation of the sympathetic system, reduced risk of arrhythmias and reduced acute thrombosis risk. These benefits could be particularly critical in the peri-event period when patients are at increased risk of complications or repeat events. Thus even if relapse occurs at a later stage, abstinence around the time of an event could prove beneficial.

When we previously evaluated varenicline to NRT and bupropion, we had data from only 4 trials.9 This evaluation found that the addition of 7 trials continues to demonstrate elevated varenicline effects compared to NRT and bupropion. Further community effectiveness interventions will be required to ensure generalizability.

There are several strengths and limitations to consider when interpreting our analysis. Strengths of this review include the comprehensive search strategy that improved the likelihood of identifying all relevant studies. Duplicate extraction of data reduced the potential for bias in this component of the synthesis process. By limiting this review to randomized trials we ensured that the included studies would have reduced likelihood of systematic error and therefore have high internal validity. Our use of meta-regression to identify sources of heterogeneity in the meta-analyses is a strength and demonstrated that several of the a priori chosen covariates were predictors of heterogeneity. To reduce patient-reporting bias, we included only studies that chemically confirmed the cessation of smoking at the specific time-points- this has been a weakness in previous reviews.23

Limitations of this meta-analysis include the potential for publication bias, in particular the possibility that small negative studies would not be published. Publication bias on short-term effects is likely due to both author-initiated bias and journal-initiated bias against short-term evaluations. We included only published trials so it is possible that other trials have been conducted and never published. However, it is unlikely that the presence of these studies would have altered the findings of our analysis given the large number of studies included and the consistency with the longer-term evaluations (both 6 months and one year).910 We limited our search to English language databases (although we would include non-English articles if identified) so the possibility of quality studies in other languages does exist. We used both direct and indirect comparisons to evaluate the relative effectiveness of agents. Head-to-head trials provide the strongest inferences regarding intervention superiority.34 In the presence of existing head-to-head trials of varenicline versus NRT.188 and bupropion,.163164 it is arguable whether indirect comparisons are required.199 In this case, the results were consistent. We used the indirect comparison method proposed by Bucher et al., that respects the principle of randomization between trials.200 Other strategies we have previously applied,.201 including mixed treatment comparisons, offer similar benefits.199

Conclusion

In conclusion, our review demonstrates clear efficacy of smoking cessation pharmacotherapies in the short term and provides similar estimates of efficacy as longer term evaluations.910 Given the benefits of smoking abstinence in both primary and secondary prevention of major morbidities, the use of these therapies in patients with active smoking related disease warrants further study.15 Future research to evaluate the efficacy and safety of these interventions in combination and in patients with advanced diseases is warranted.

Abbreviations

CO: Carbon monoxide; NRT: Nicotine replacement therapy; OR: Odds ratio; RCT: Randomized Clinical Trial; SCN: Saliva thiocynate; 95% CI: 95% Confidence intervals.

Competing interests

EM, PW and KW have consulted to Pfizer Ltd in the past 5 years. No stock ownership is reported. DS is an employee of Pfizer Ltd. JE declares no conflict of interest. Pfizer Ltd. Is the maker of an NRT product and varenicline. EM and KW are supported by Canadian Institutes of Health Research (CIHR) Canada Research Chairs.

Authors' contributions

EM, PW, DS, KW and COR conceived the protocol. EM, PW, KW did the search strategies. EM, PW, JO, KW did the data abstraction and analysis. EM, PW, JO, KW wrote the first draft of the manuscript. EM, PW, DS, JO, KW approved the final submitted version.

Funding

This study received unrestricted funding from Pfizer Ltd to evaluate anti-smoking agents. They had no role in the conduct, interpretation or writing of this manuscript.

Acknowledgements

We thank Chris O'Regan for assistance with this study.

Mortality from smoking worldwide Peto R Lopez AD Boreham J Thun M Heath C Jr Doll R Br Med Bull 1996 52 12 21 8746293 An analysis of the effectiveness of interventions intended to help people stop smoking Law M Tang JL Arch Intern Med 1995 155 1933 1941 10.1001/archinte.155.18.1933 7575046 Updated US smoking cessation guideline advises counseling, combing therapies Kuehn BM JAMA 2008 299 2736 10.1001/jama.299.23.2736 18559995 US Public Health Service. Treating Tobacco Use and Dependence: 2008 Update 2008 http://www.ahrq.gov/path/tobacco.htm Nicotine replacement therapy for smoking cessation Silagy C Lancaster T Stead L Mant D Fowler G Cochrane Database Syst Rev 2004 CD000146 15266423 Exploring the geometry of treatment networks Salanti G Kavvoura FK Ioannidis JP Ann Intern Med 2008 148 544 553 18378949 Antidepressants for smoking cessation Hughes J Stead L Lancaster T Cochrane Database Syst Rev 2004 CD000031 15494986 Systematic review and meta-analysis of combination therapy for smoking cessation Shah SD Wilken LA Winkler SR Lin SJ J Am Pharm Assoc (2003) 2008 48 659 665 10.1331/JAPhA.2008.07063 18826906 Effectiveness of smoking cessation therapies: a systematic review and meta-analysis Wu P Wilson K Dimoulas P Mills EJ BMC Public Health 2006 6 300 1764891 17156479 10.1186/1471-2458-6-300 Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials Eisenberg MJ Filion KB Yavin D Belisle P Mottillo S Joseph L Gervais A O'Loughlin J Paradis G Rinfret S Pilote L Cmaj 2008 179 135 144 2443223 18625984 Nicotine receptor partial agonists for smoking cessation Cahill K Stead LF Lancaster T Cochrane Database Syst Rev 2008 CD006103 18646137 Nicotine replacement therapy for smoking cessation Stead LF Perera R Bullen C Mant D Lancaster T Cochrane Database Syst Rev 2008 CD000146 18253970 Antidepressants for smoking cessation Hughes JR Stead LF Lancaster T Cochrane Database Syst Rev 2007 CD000031 17253443 NICE: smoking cessation guidance NICE 2008 http://www.idea.gov.uk/idk/core/pagedo?pageId=8024618 Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies Wilson K Gibson N Willan A Cook D Arch Intern Med 2000 160 939 944 10.1001/archinte.160.7.939 10761958 Effect of preoperative smoking cessation interventions on postoperative complications and smoking cessation Thomsen T Tonnesen H Moller AM The British journal of surgery 2009 96 451 461 10.1002/bjs.6591 19358172 Evaluation of two biological markers of tobacco exposure. MRFIT Research Group Ruth KJ Neaton JD Prev Med 1991 20 574 589 10.1016/0091-7435(91)90056-A 1758839 Hounton SH, Carabin H, Henderson NJ. Towards an understanding of barriers to condom use in rural Benin using the Health Belief Model: a cross sectional survey BMC Public Health 2005 5 8 547902 15663784 10.1186/1471-2458-5-8 Training health professionals in smoking cessation Lancaster T Silagy C Fowler G Cochrane Database Syst Rev 2000 CD000214 10908465 Physician advice for smoking cessation Silagy C Cochrane Database Syst Rev 2000 CD000165 10796499 Nicotine replacement therapy for smoking cessation Silagy C Lancaster T Stead L Mant D Fowler G Cochrane Database Syst Rev 2001 CD000146 11686953 Nicotine replacement therapy for smoking cessation Silagy C Lancaster T Stead L Mant D Fowler G Cochrane Database Syst Rev 2002 CD000146 12519537 Nicotine replacement therapy for smoking cessation Silagy C Mant D Fowler G Lancaster T Cochrane Database Syst Rev 2000 CD000146 Nicotine replacement therapy for smoking cessation Silagy C Mant D Fowler G Lancaster T Cochrane Database Syst Rev 2000 CD000146 Updating a systematic review--what difference did it make? Case study of nicotine replacement therapy Stead LF Lancaster T Silagy CA BMC Med Res Methodol 2001 1 10 60653 11734066 10.1186/1471-2288-1-10 Antidepressants for smoking cessation Hughes JR Stead LF Lancaster T Cochrane Database Syst Rev 2002 CD000031 11869562 TA39 Smoking cessation - bupropion and nicotine replacement therapy: Guidance. Issue Date: March 2002 Review Date: March 2005 NICE http://www.nice.org.uk/TA039 Agreement between alternative classifications of acute respiratory distress syndrome Meade MO Guyatt GH Cook RJ Groll R Kachura JR Wigg M Cook DJ Slutsky AS Stewart TE Am J Respir Crit Care Med 2001 163 490 493 11179128 Combination of log relative risk in retrospective studies of disease Sheehe PR Am J Public Health Nations Health 1966 56 1745 1750 1257309 5951494 The statistical basis of meta-analysis Fleiss JL Stat Methods Med Res 1993 2 121 145 10.1177/096228029300200202 8261254 Meta-analysis in clinical trials DerSimonian R Laird N Control Clin Trials 1986 7 177 188 10.1016/0197-2456(86)90046-2 3802833 Quantifying heterogeneity in a meta-analysis Higgins JP Thompson SG Stat Med 2002 21 1539 1558 10.1002/sim.1186 12111919 How should meta-regression analyses be undertaken and interpreted? Thompson SG Higgins JP Stat Med 2002 21 1559 1573 10.1002/sim.1187 12111920 Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect McAlister FA Laupacis A Wells GA Sackett DL Jama 1999 282 1371 1377 10.1001/jama.282.14.1371 10527185 Systematic review on the risk and benefit of different cholesterol-lowering interventions Bucher HC Griffith LE Guyatt GH Arterioscler Thromb Vasc Biol 1999 19 187 195 9974397 Randomised controlled trial of nicotine chewing-gum Jarvis MJ Raw M Russell MA Feyerabend C Br Med J (Clin Res Ed) 1982 285 537 540 1499070 6809161 10.1136/bmj.285.6341.537 A comparison of psychological and pharmacological treatment in smoking cessation Fagerstrom KO J Behav Med 1982 5 343 351 10.1007/BF00846161 7131548 The use of nicotine chewing gum as an aid to stopping smoking Malcolm RE Sillett RW Turner JA Ball KP Psychopharmacology (Berl) 1980 70 295 296 10.1007/BF00427889 6777804 Comparison of four methods of smoking withdrawal in patients with smoking related diseases. Report by a subcommittee of the Research Committee of the British Thoracic Society Br Med J (Clin Res Ed) 1983 286 595 597 1546807 6402162 10.1136/bmj.286.6365.595 Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial Schneider NG Jarvik ME Forsythe AB Read LL Elliott ML Schweiger A Addict Behav 1983 8 253 261 10.1016/0306-4603(83)90020-5 6666689 Placebo controlled trial of nicotine chewing gum in general practice Jamrozik K Fowler G Vessey M Wald N Br Med J (Clin Res Ed) 1984 289 794 797 1442980 6434084 10.1136/bmj.289.6448.794 Nicotine gum and behavioral treatment: a placebo controlled trial Hall SM Tunstall CD Ginsberg D Benowitz NL Jones RT J Consult Clin Psychol 1987 55 603 605 10.1037/0022-006X.55.4.603 3624619 Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up Tonnesen P Fryd V Hansen M Helsted J Gunnersen AB Forchammer H Stockner M Addict Behav 1988 13 17 27 10.1016/0306-4603(88)90021-4 3284283 Smoking cessation through the use of nicotine chewing gum: a double-blind trial in Thailand Areechon W Punnotok J Clin Ther 1988 10 183 186 3078903 Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford Stop Smoking Project Fortmann SP Killen JD Telch MJ Newman B Jama 1988 260 1575 1580 10.1001/jama.260.11.1575 3045351 Nicotine vs placebo gum in general medical practice Hughes JR Gust SW Keenan RM Fenwick JW Healey ML Jama 1989 261 1300 1305 10.1001/jama.261.9.1300 2644465 Controlled trial of nicotine polacrilex gum with supportive measures Blondal T Arch Intern Med 1989 149 1818 1821 10.1001/archinte.149.8.1818 2669665 Nicotine replacement: effects of postcessation weight gain Gross J Stitzer ML Maldonado J J Consult Clin Psychol 1989 57 87 92 10.1037/0022-006X.57.1.87 2925978 Effectiveness of a transdermal nicotine system in smoking cessation studies Abelin T Ehrsam R Buhler-Reichert A Imhof PR Muller P Thommen A Vesanen K Methods Find Exp Clin Pharmacol 1989 11 205 214 2657276 Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention Killen JD Fortmann SP Newman B Varady A J Consult Clin Psychol 1990 58 85 92 10.1037/0022-006X.58.1.85 2319049 Nicotine-replacement therapy with use of a transdermal nicotine patch--a randomized double-blind placebo-controlled trial Hurt RD Lauger GG Offord KP Kottke TE Dale LC Mayo Clin Proc 1990 65 1529 1537 2255215 A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation Tonnesen P Norregaard J Simonsen K Sawe U N Engl J Med 1991 325 311 315 2057036 Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum Campbell IA Prescott RJ Tjeder-Burton SM Respir Med 1991 85 155 157 10.1016/S0954-6111(06)80295-7 1887134 Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study Daughton DM Heatley SA Prendergast JJ Causey D Knowles M Rolf CN Cheney RA Hatlelid K Thompson AB Rennard SI Arch Intern Med 1991 151 749 752 10.1001/archinte.151.4.749 2012458 Randomised controlled trial of nasal nicotine spray in smoking cessation Sutherland G Stapleton JA Russell MA Jarvis MJ Hajek P Belcher M Feyerabend C Lancet 1992 340 324 329 10.1016/0140-6736(92)91403-U 1353803 Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling Sachs DP Sawe U Leischow SJ Arch Intern Med 1993 153 1881 1890 10.1001/archinte.153.16.1881 8110249 A double-blind trial of a nicotine inhaler for smoking cessation Tonnesen P Norregaard J Mikkelsen K Jorgensen S Nilsson F Jama 1993 269 1268 1271 10.1001/jama.269.10.1268 8437304 Transdermal nicotine in smoking cessation and involvement of non-specific influences Merz PG Keller-Stanislawski B Huber T Woodcock BG Rietbrock N Int J Clin Pharmacol Ther Toxicol 1993 31 476 482 8262685 Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches Russell MA Stapleton JA Feyerabend C Wiseman SM Gustavsson G Sawe U Connor P Bmj 1993 306 1308 1312 1677738 8518572 10.1136/bmj.306.6888.1308 The nicotine patch in smoking cessation. A randomized trial with telephone counseling Westman EC Levin ED Rose JE Arch Intern Med 1993 153 1917 1923 10.1001/archinte.153.16.1917 8250653 Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study Hjalmarson A Franzon M Westin A Wiklund O Arch Intern Med 1994 154 2567 2572 10.1001/archinte.154.22.2567 7979853 Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement Hurt RD Dale LC Fredrickson PA Caldwell CC Lee GA Offord KP Lauger GG Marusic Z Neese LW Lundberg TG Jama 1994 271 595 600 10.1001/jama.271.8.595 8301791 Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments Fiore MC Kenford SL Jorenby DE Wetter DW Smith SS Baker TB Chest 1994 105 524 533 10.1378/chest.105.2.524 8306757 The transdermal nicotine patch: results of a randomised placebo-controlled trial Richmond RL Harris K de Almeida Neto A Med J Aust 1994 161 130 135 8028537 Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking Levin ED Westman EC Stein RM Carnahan E Sanchez M Herman S Behm FM Rose JE J Clin Psychopharmacol 1994 14 41 49 10.1097/00004714-199402000-00006 8151002 Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice Stapleton JA Russell MA Feyerabend C Wiseman SM Gustavsson G Sawe U Wiseman D Addiction 1995 90 31 42 10.1111/j.1360-0443.1995.tb01007.x 7888977 Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program Herrera N Franco R Herrera L Partidas A Rolando R Fagerstrom KO Chest 1995 108 447 451 10.1378/chest.108.2.447 7634882 Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial Schneider NG Olmstead R Mody FV Doan K Franzon M Jarvik ME Steinberg C Addiction 1995 90 1671 1682 10.1111/j.1360-0443.1995.tb02837.x 8555958 Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia Puska PKH Vartiainen E Urjanheimo E Tabacco Control 1995 4 231 235 10.1136/tc.4.3.231 Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial Kornitzer M Boutsen M Dramaix M Thijs J Gustavsson G Prev Med 1995 24 41 47 10.1006/pmed.1995.1006 7740014 High-dose nicotine patch therapy. Percentage of replacement and smoking cessation Dale LC Hurt RD Offord KP Lawson GM Croghan IT Schroeder DR Jama 1995 274 1353 1358 10.1001/jama.274.17.1353 7563559 Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study Campbell IA Prescott RJ Tjeder-Burton SM Respir Med 1996 90 47 51 10.1016/S0954-6111(96)90244-9 8857326 Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers Gourlay SG Forbes A Marriner T Pethica D McNeil JJ Bmj 1995 311 363 366 2550432 7640544 Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study Hall SM Munoz RF Reus VI Sees KL Duncan C Humfleet GL Hartz DT J Consult Clin Psychol 1996 64 1003 1009 10.1037/0022-006X.64.5.1003 8916629 Efficacy of the Nicotine Inhaler as an Adjunct to Smoking Cessation Leischow SJN Franzo F Hill M Otte A Merikle P P E American Journal of Health Behavior 1996 20 364 371 Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial Schneider NG Olmstead R Nilsson F Mody FV Franzon M Doan K Addiction 1996 91 1293 1306 10.1111/j.1360-0443.1996.tb03616.x 8854366 Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch Paoletti P Fornai E Maggiorelli F Puntoni R Viegi G Carrozzi L Corlando A Gustavsson G Sawe U Giuntini C Eur Respir J 1996 9 643 651 10.1183/09031936.96.09040643 8726925 Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement Kinnunen T Doherty K Militello FS Garvey AJ J Consult Clin Psychol 1996 64 791 798 10.1037/0022-006X.64.4.791 8803370 Nicotine patch and self-help video for cigarette smoking cessation Killen JD Fortmann SP Davis L Varady A J Consult Clin Psychol 1997 65 663 672 10.1037/0022-006X.65.4.663 9256568 A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation Blondal T Franzon M Westin A Eur Respir J 1997 10 1585 1590 10.1183/09031936.97.10071585 9230252 The nicotine inhaler in smoking cessation Hjalmarson A Nilsson F Sjostrom L Wiklund O Arch Intern Med 1997 157 1721 1728 10.1001/archinte.157.15.1721 9250233 Nicotine patches in smoking cessation: a randomized trial among over-the-counter customers in Denmark Sonderskov J Olsen J Sabroe S Meillier L Overvad K Am J Epidemiol 1997 145 309 318 9054234 Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group Daughton D Susman J Sitorius M Belenky S Millatmal T Nowak R Patil K Rennard SI Arch Fam Med 1998 7 425 430 10.1001/archfami.7.5.425 9755734 Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation Perng RP Hsieh WC Chen YM Lu CC Chiang SJ J Formos Med Assoc 1998 97 547 551 9747065 Smoking cessation among inner-city African Americans using the nicotine transdermal patch Ahluwalia JS McNagny SE Clark WS J Gen Intern Med 1998 13 1 8 1496888 9462488 10.1046/j.1525-1497.1998.00001.x Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial Lewis SF Piasecki TM Fiore MC Anderson JE Baker TB Prev Med 1998 27 296 303 10.1006/pmed.1998.0266 9579010 Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation Davidson M Epstein M Burt R Schaefer C Whitworth G McDonald A Arch Fam Med 1998 7 569 574 10.1001/archfami.7.6.569 9821833 Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up Blondal T Gudmundsson LJ Olafsdottir I Gustavsson G Westin A Bmj 1999 318 285 288 27708 9924052 Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society Tonnesen P Paoletti P Gustavsson G Russell MA Saracci R Gulsvik A Rijcken B Sawe U Eur Respir J 1999 13 238 246 10.1034/j.1399-3003.1999.13b04.x 10065662 Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials Hays JT Croghan IT Schroeder DR Offord KP Hurt RD Wolter TD Nides MA Davidson M Am J Public Health 1999 89 1701 1707 1508975 10553392 10.2105/AJPH.89.11.1701 Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial Bohadana A Nilsson F Rasmussen T Martinet Y Arch Intern Med 2000 160 3128 3134 10.1001/archinte.160.20.3128 11074742 Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety Bolliger CT Zellweger JP Danielsson T van Biljon X Robidou A Westin A Perruchoud AP Sawe U Bmj 2000 321 329 333 27447 10926587 10.1136/bmj.321.7257.329 Effects of nicotine gum dose by level of nicotine dependence Garvey AJ Kinnunen T Nordstrom BL Utman CH Doherty K Rosner B Vokonas PS Nicotine Tob Res 2000 2 53 63 10.1080/14622200050011303 11072441 A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation Wallstrom M Nilsson F Hirsch JM Addiction 2000 95 1161 1171 11092064 Nicotine patches for pregnant smokers: A randomized controlled study Wisborg K Henriksen TB Jespersen LB Secher NJ Obstet Gynecol 2000 96 967 971 10.1016/S0029-7844(00)01071-1 11084187 Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial Etter JF Laszlo E Zellweger JP Perrot C Perneger TV J Clin Psychopharmacol 2002 22 487 495 10.1097/00004714-200210000-00008 12352272 Efficacy of over-the-counter nicotine patch Shiffman S Gorsline J Gorodetzky CW Nicotine Tob Res 2002 4 477 483 10.1080/1462220021000018416 12521407 A comparison of a nicotine sublingual tablet and placebo for smoking cessation Glover ED Glover PN Franzon M Sullivan CR Cerullo CC Howell RM Keyes GG Nilsson F Hobbs GR Nicotine Tob Res 2002 4 441 450 10.1080/1462220021000018443 12521403 Efficacy of a nicotine lozenge for smoking cessation Shiffman S Dresler CM Hajek P Gilburt SJ Targett DA Strahs KR Arch Intern Med 2002 162 1267 1276 10.1001/archinte.162.11.1267 12038945 Smoking cessation with nicotine replacement therapy among health care workers: randomized double-blind study Glavas D Rumboldt M Rumboldt Z Croat Med J 2003 44 219 224 12698515 Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up Wennike P Danielsson T Landfeldt B Westin A Tonnesen P Addiction 2003 98 1395 1402 10.1046/j.1360-0443.2003.00489.x 14519176 Efficacy of nicotine patch in smokers with a history of alcoholism Hughes JR Novy P Hatsukami DK Jensen J Callas PW Alcohol Clin Exp Res 2003 27 946 954 12824815 Treatment of adolescent smokers with the nicotine patch Hanson K Allen S Jensen S Hatsukami D Nicotine Tob Res 2003 5 515 526 10.1080/14622200307243 12959789 The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia Chou KR Chen R Lee JF Ku CH Lu RB Int J Nurs Stud 2004 41 321 330 10.1016/j.ijnurstu.2003.07.001 14967189 Effect of pre-treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial Schuurmans MM Diacon AH van Biljon X Bolliger CT Addiction 2004 99 634 640 10.1111/j.1360-0443.2004.00711.x 15078238 Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction Moolchan ET Robinson ML Ernst M Cadet JL Pickworth WB Heishman SJ Schroeder JR Pediatrics 2005 115 e407 414 10.1542/peds.2004-1894 15805342 Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study Batra A Klingler K Landfeldt B Friederich HM Westin A Danielsson T Clin Pharmacol Ther 2005 78 689 696 10.1016/j.clpt.2005.08.019 16338284 A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women Cooper TV Klesges RC Debon MW Zbikowski SM Johnson KC Clemens LH Addict Behav 2005 30 61 75 10.1016/j.addbeh.2004.04.013 15561449 Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial Rennard SI Glover ED Leischow S Daughton DM Glover PN Muramoto M Franzon M Danielsson T Landfeldt B Westin A Nicotine Tob Res 2006 8 555 564 10.1080/14622200600789916 16920653 Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support Tonnesen P Mikkelsen K Bremann L Chest 2006 130 334 342 10.1378/chest.130.2.334 16899830 The effects of nicotine gum and counseling among African American light smokers: a 2 × 2 factorial design Ahluwalia JS Okuyemi K Nollen N Choi WS Kaur H Pulvers K Mayo MS Addiction 2006 101 883 891 10.1111/j.1360-0443.2006.01461.x 16696632 Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches Myung SK Seo HG Park S Kim Y Kim DJ Lee do H Seong MW Nam MH Oh SW Kim JA Kim MY J Korean Med Sci 2007 22 1065 1070 2694636 18162724 10.3346/jkms.2007.22.6.1065 A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse Covey LS Glassman AH Jiang H Fried J Masmela J LoDuca C Petkova E Rodriguez K Addiction 2007 102 1292 1302 10.1111/j.1360-0443.2007.01887.x 17624979 Efficacy of bupropion alone and in combination with nicotine gum Piper ME Federman EB McCarthy DE Bolt DM Smith SS Fiore MC Baker TB Nicotine Tob Res 2007 9 947 954 10.1080/14622200701540820 17763111 Transdermal nicotine for smoking cessation in postmenopausal women Oncken C Cooney J Feinn R Lando H Kranzler HR Addict Behav 2007 32 296 309 10.1016/j.addbeh.2006.04.004 16765526 Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention Croghan IT Hurt RD Dakhil SR Croghan GA Sloan JA Novotny PJ Rowland KM Bernath A Loots ML Le-Lindqwister NA Tschetter LK Garneau SC Flynn KA Ebbert LP Wender DB Loprinzi CL Mayo Clin Proc 2007 82 186 195 10.4065/82.2.186 17290726 Helping people to stop smoking: randomised comparison of groups being treated with acupuncture and nicotine gum with control group Clavel F Benhamou S Company-Huertas A Flamant R Br Med J (Clin Res Ed) 1985 291 1538 1539 1418170 3933739 10.1136/bmj.291.6508.1538 Effects of nicotine chewing gum and follow-up appointments in physician-based smoking cessation Fagerstrom KO Prev Med 1984 13 517 527 10.1016/0091-7435(84)90020-3 6396639 Nicotine gum and behavioral treatment in smoking cessation Hall SM Tunstall C Rugg D Jones RT Benowitz N J Consult Clin Psychol 1985 53 256 258 10.1037/0022-006X.53.2.256 3998252 Effect of nicotine chewing gum as an adjunct to general practitioner's advice against smoking Russell MA Merriman R Stapleton J Taylor W Br Med J (Clin Res Ed) 1983 287 1782 1785 1549849 6416593 10.1136/bmj.287.6407.1782 Smoking cessation in family practice: the effects of advice and nicotine chewing gum prescription Page AR Walters DJ Schlegel RP Best JA Addict Behav 1986 11 443 446 10.1016/0306-4603(86)90025-0 3812055 Smoking intervention in the workplace using videotapes and nicotine chewing gum Sutton S Hallett R Prev Med 1988 17 48 59 10.1016/0091-7435(88)90071-0 3362801 Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context Harackiewicz JM Blair LW Sansone C Epstein JA Stuchell RN Addict Behav 1988 13 319 330 10.1016/0306-4603(88)90038-X 3239463 Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking Tonnesen P Fryd V Hansen M Helsted J Gunnersen AB Forchammer H Stockner M N Engl J Med 1988 318 15 18 3336380 Smoking cessation in primary care. A randomized controlled trial of nicotine-bearing chewing gum Gilbert JR Wilson DM Best JA Taylor DW Lindsay EA Singer J Willms DG J Fam Pract 1989 28 49 55 2643672 A randomized trial of smoking cessation interventions in general practice in Italy Segnan N Ponti A Battista RN Senore C Rosso S Shapiro SH Aimar D Cancer Causes Control 1991 2 239 246 10.1007/BF00052140 1873454 Increasing the efficacy of physician-delivered smoking interventions: a randomized clinical trial Ockene JK Kristeller J Goldberg R Amick TL Pekow PS Hosmer D Quirk M Kalan K J Gen Intern Med 1991 6 1 8 10.1007/BF02599381 1999742 An assessment of nicotine gum as an adjunct to freedom from smoking cessation clinics McGovern PG Lando HA Addict Behav 1992 17 137 147 10.1016/0306-4603(92)90018-Q 1585841 Smoking cessation in women concerned about weight Pirie PL McBride CM Hellerstedt W Jeffery RW Hatsukami D Allen S Lando H Am J Public Health 1992 82 1238 1243 1694323 1503165 10.2105/AJPH.82.9.1238 Does nurse counseling or offer of nicotine gum improve the effectiveness of physician smoking-cessation advice? Nebot M Cabezas C Fam Pract Res J 1992 12 263 270 1414430 One-year evaluation of three smoking cessation interventions administered by general practitioners Richmond RL Makinson RJ Kehoe LA Giugni AA Webster IW Addict Behav 1993 18 187 199 10.1016/0306-4603(93)90049-F 8506790 Matching high- and low-dependence smokers to self-help treatment with or without nicotine replacement Niaura R Goldstein MG Abrams DB Prev Med 1994 23 70 77 10.1006/pmed.1994.1010 8016036 Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment Fortmann SP Killen JD J Consult Clin Psychol 1995 63 460 468 10.1037/0022-006X.63.3.460 7608359 Dose effects of nicotine gum Gross J Johnson J Sigler L Stitzer ML Addict Behav 1995 20 371 381 10.1016/0306-4603(94)00078-D 7653318 Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping Cinciripini PM Cinciripini LG Wallfisch A Haque W Van Vunakis H J Consult Clin Psychol 1996 64 314 323 10.1037/0022-006X.64.2.314 8871416 Effects of smoking cessation on insulin and cardiovascular risk factors--a controlled study of 4 months' duration Nilsson P Lundgren H Soderstrom M Fagerstrom KO Nilsson-Ehle P J Intern Med 1996 240 189 194 10.1046/j.1365-2796.1996.16844000.x 8918509 Prospective evaluation of three smoking interventions in 205 recovering alcoholics: one-year results of Project SCRAP-Tobacco Martin JE Calfas KJ Patten CA Polarek M Hofstetter CR Noto J Beach D J Consult Clin Psychol 1997 65 190 194 10.1037/0022-006X.65.1.190 9103749 Cue exposure treatment for smoking relapse prevention: a controlled clinical trial Niaura R Abrams DB Shadel WG Rohsenow DJ Monti PM Sirota AD Addiction 1999 94 685 695 10.1046/j.1360-0443.1999.9456856.x 10563033 Smoking cessation with four nicotine replacement regimes in a lung clinic Tonnesen P Mikkelsen KL Eur Respir J 2000 16 717 722 10.1034/j.1399-3003.2000.16d25.x 11106218 Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support Hand S Edwards S Campbell IA Cannings R Thorax 2002 57 715 718 1746389 12149533 10.1136/thorax.57.8.715 Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients Molyneux A Lewis S Leivers U Anderton A Antoniak M Brackenridge A Nilsson F McNeill A West R Moxham J Britton J Thorax 2003 58 484 488 1746718 12775857 10.1136/thorax.58.6.484 Controlled trial for smoking cessation in a Navy shipboard population using nicotine patch, sustained-release buproprion, or both Swanson NA Burroughs CC Long MA Lee RW Mil Med 2003 168 830 834 14620649 A randomized trial of smoking cessation. Medication versus motivation Uyar M Filiz A Bayram N Elbek O Herken H Topcu A Dikensoy O Ekinci E Saudi Med J 2007 28 922 926 17530112 Nicotine replacement and behavioral therapy for smoking cessation in pregnancy Pollak KI Oncken CA Lipkus IM Lyna P Swamy GK Pletsch PK Peterson BL Heine RP Brouwer RJ Fish L Myers ER Am J Prev Med 2007 33 297 305 10.1016/j.amepre.2007.05.006 17888856 The effects of exercise and nicotine replacement therapy on smoking rates in women Prapavessis H Cameron L Baldi JC Robinson S Borrie K Harper T Grove JR Addict Behav 2007 32 1416 1432 10.1016/j.addbeh.2006.10.005 17097814 Pathways to health: a cluster randomized trial of nicotine gum and motivational interviewing for smoking cessation in low-income housing Okuyemi KS James AS Mayo MS Nollen N Catley D Choi WS Ahluwalia JS Health Educ Behav 2007 34 43 54 10.1177/1090198106288046 16778147 A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses Gallagher SM Penn PE Schindler E Layne W J Psychoactive Drugs 2007 39 487 497 18303706 A randomised-controlled pilot study using nicotine patches with pregnant women Hotham ED Gilbert AL Atkinson ER Addict Behav 2006 31 641 648 10.1016/j.addbeh.2005.05.042 15985339 A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation Jorenby DE Leischow SJ Nides MA Rennard SI Johnston JA Hughes AR Smith SS Muramoto ML Daughton DM Doan K Fiore MC Baker TB N Engl J Med 1999 340 685 691 10.1056/NEJM199903043400903 10053177 Randomised trial of nicotine patches in general practice: results at one year. Imperial Cancer Research Fund General Practice Research Group Bmj 1994 308 1476 1477 2540289 8019282 A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia George TP Vessicchio JC Sacco KA Weinberger AH Dudas MM Allen TM Creeden CL Potenza MN Feingold A Jatlow PI Biol Psychiatry 2008 63 1092 1096 2693008 18096137 10.1016/j.biopsych.2007.11.002 A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling McCarthy DE Piasecki TM Lawrence DL Jorenby DE Shiffman S Fiore MC Baker TB Nicotine Tob Res 2008 10 717 729 10.1080/14622200801968343 18418793 Bupropion and cognitive-behavioral therapy for smoking cessation in women Schmitz JM Stotts AL Mooney ME Delaune KA Moeller GF Nicotine Tob Res 2007 9 699 709 10.1080/14622200701365335 17558827 A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care Fossati R Apolone G Negri E Compagnoni A La Vecchia C Mangano S Clivio L Garattini S Arch Intern Med 2007 167 1791 1797 10.1001/archinte.167.16.1791 17846399 A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia Evins AE Cather C Culhane MA Birnbaum A Horowitz J Hsieh E Freudenreich O Henderson DC Schoenfeld DA Rigotti NA Goff DC J Clin Psychopharmacol 2007 27 380 386 10.1097/01.jcp.0b013e3180ca86fa 17632223 Bupropion and nicotine patch as smoking cessation aids in alcoholics Grant KM Kelley SS Smith LM Agrawal S Meyer JR Romberger DJ Alcohol 2007 41 381 391 2064868 17889314 10.1016/j.alcohol.2007.03.011 Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation Muramoto ML Leischow SJ Sherrill D Matthews E Strayer LJ Arch Pediatr Adolesc Med 2007 161 1068 1074 10.1001/archpedi.161.11.1068 17984409 Bupropion and cognitive-behavioral treatment for depression in smoking cessation Brown RA Niaura R Lloyd-Richardson EE Strong DR Kahler CW Abrantes AM Abrams D Miller IW Nicotine Tob Res 2007 9 721 730 2213513 17577801 10.1080/14622200701416955 Bupropion for smokers hospitalized with acute cardiovascular disease Rigotti NA Thorndike AN Regan S McKool K Pasternak RC Chang Y Swartz S Torres-Finnerty N Emmons KM Singer DE Am J Med 2006 119 1080 1087 10.1016/j.amjmed.2006.04.024 17145253 A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results Haggstram FM Chatkin JM Sussenbach-Vaz E Cesari DH Fam CF Fritscher CC Pulm Pharmacol Ther 2006 19 205 209 10.1016/j.pupt.2005.05.003 16517193 Extended treatment with bupropion SR for cigarette smoking cessation Killen JD Fortmann SP Murphy GM Jr Hayward C Arredondo C Cromp D Celio M Abe L Wang Y Schatzberg AF J Consult Clin Psychol 2006 74 286 294 10.1037/0022-006X.74.2.286 16649873 Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up Nides M Oncken C Gonzales D Rennard S Watsky EJ Anziano R Reeves KR Arch Intern Med 2006 166 1561 1568 10.1001/archinte.166.15.1561 16908788 Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial Gonzales D Rennard SI Nides M Oncken C Azoulay S Billing CB Watsky EJ Gong J Williams KE Reeves KR Jama 2006 296 47 55 10.1001/jama.296.1.47 16820546 Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial Jorenby DE Hays JT Rigotti NA Azoulay S Watsky EJ Williams KE Billing CB Gong J Reeves KR Jama 2006 296 56 63 10.1001/jama.296.1.56 16820547 A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia Evins AE Cather C Deckersbach T Freudenreich O Culhane MA Olm-Shipman CM Henderson DC Schoenfeld DA Goff DC Rigotti NA J Clin Psychopharmacol 2005 25 218 225 10.1097/01.jcp.0000162802.54076.18 15876899 Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease Wagena EJ Knipschild PG Huibers MJ Wouters EF van Schayck CP Arch Intern Med 2005 165 2286 2292 10.1001/archinte.165.19.2286 16246996 Efficacy of bupropion in the indigenous Maori population in New Zealand Holt S Timu-Parata C Ryder-Lewis S Weatherall M Beasley R Thorax 2005 60 120 123 1747282 15681499 10.1136/thx.2004.030239 Bupropion SR vs placebo for smoking cessation in health care professionals Zellweger JP Boelcskei PL Carrozzi L Sepper R Sweet R Hider AZ Am J Health Behav 2005 29 240 249 15899687 Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial Myles PS Leslie K Angliss M Mezzavia P Lee L Anaesthesia 2004 59 1053 1058 10.1111/j.1365-2044.2004.03943.x 15479310 Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial Aubin HJ Lebargy F Berlin I Bidaut-Mazel C Chemali-Hudry J Lagrue G Addiction 2004 99 1206 1218 10.1111/j.1360-0443.2004.00814.x 15317642 A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees Dalsgareth OJ Hansen NC Soes-Petersen U Evald T Hoegholm A Barber J Vestbo J Nicotine Tob Res 2004 6 55 61 14982688 Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking Hatsukami DK Rennard S Patel MK Kotlyar M Malcolm R Nides MA Dozier G Bars MP Jamerson BD Am J Med 2004 116 151 157 10.1016/j.amjmed.2003.07.018 14749158 Bupropion for smoking cessation: a randomized trial Simon JA Duncan C Carmody TP Hudes ES Arch Intern Med 2004 164 1797 1803 10.1001/archinte.164.16.1797 15364675 Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers Killen JD Robinson TN Ammerman S Hayward C Rogers J Stone C Samuels D Levin SK Green S Schatzberg AF J Consult Clin Psychol 2004 72 729 735 10.1037/0022-006X.72.4.729 15301658 Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study Tonstad S Farsang C Klaene G Lewis K Manolis A Perruchoud AP Silagy C van Spiegel PI Astbury C Hider A Sweet R Eur Heart J 2003 24 946 955 10.1016/S0195-668X(03)00003-4 12714026 A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation Tonnesen P Tonstad S Hjalmarson A Lebargy F Van Spiegel PI Hider A Sweet R Townsend J J Intern Med 2003 254 184 192 10.1046/j.1365-2796.2003.01185.x 12859700 Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking Hurt RD Krook JE Croghan IT Loprinzi CL Sloan JA Novotny PJ Kardinal CG Knost JA Tirona MT Addo F Morton RF Michalak JC Schaefer PL Porter PA Stella PJ J Clin Oncol 2003 21 914 920 10.1200/JCO.2003.08.160 12610193 Pharmacogenetic investigation of smoking cessation treatment Lerman C Shields PG Wileyto EP Audrain J Pinto A Hawk L Krishnan S Niaura R Epstein L Pharmacogenetics 2002 12 627 634 10.1097/00008571-200211000-00007 12439223 Mediating mechanisms for the impact of bupropion in smoking cessation treatment Lerman C Roth D Kaufmann V Audrain J Hawk L Liu A Niaura R Epstein L Drug Alcohol Depend 2002 67 219 223 10.1016/S0376-8716(02)00067-4 12095672 A placebo controlled trial of bupropion for smoking cessation in schizophrenia George TP Vessicchio JC Termine A Bregartner TA Feingold A Rounsaville BJ Kosten TR Biol Psychiatry 2002 52 53 61 10.1016/S0006-3223(02)01339-2 12079730 Psychological intervention and antidepressant treatment in smoking cessation Hall SM Humfleet GL Reus VI Munoz RF Hartz DT Maude-Griffin R Arch Gen Psychiatry 2002 59 930 936 10.1001/archpsyc.59.10.930 12365880 Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial Tashkin D Kanner R Bailey W Buist S Anderson P Nides M Gonzales D Dozier G Patel MK Jamerson B Lancet 2001 357 1571 1575 10.1016/S0140-6736(00)04724-3 11377644 A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder Hertzberg MA Moore SD Feldman ME Beckham JC J Clin Psychopharmacol 2001 21 94 98 10.1097/00004714-200102000-00017 11199956 A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia Evins AE Mays VK Rigotti NA Tisdale T Cather C Goff DC Nicotine Tob Res 2001 3 397 403 10.1080/14622200110073920 11694208 Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study Gonzales DH Nides MA Ferry LH Kustra RP Jamerson BD Segall N Herrero LA Krishen A Sweeney A Buaron K Metz A Clin Pharmacol Ther 2001 69 438 444 10.1067/mcp.2001.115750 11406741 Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial Hays JT Hurt RD Rigotti NA Niaura R Gonzales D Durcan MJ Sachs DP Wolter TD Buist AS Johnston JA White JD Ann Intern Med 2001 135 423 433 11560455 A comparison of sustained-release bupropion and placebo for smoking cessation Hurt RD Sachs DP Glover ED Offord KP Johnston JA Dale LC Khayrallah MA Schroeder DR Glover PN Sullivan CR Croghan IT Sullivan PM N Engl J Med 1997 337 1195 1202 10.1056/NEJM199710233371703 9337378 Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial Aubin HJ Bobak A Britton JR Oncken C Billing CB Jr Gong J Williams KE Reeves KR Thorax 2008 63 717 724 2569194 18263663 10.1136/thx.2007.090647 The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial Niaura R Hays JT Jorenby DE Leone FT Pappas JE Reeves KR Williams KE Billing CB Jr Curr Med Res Opin 2008 24 1931 1941 10.1185/03007990802177523 18513462 A double-blind study evaluating the long-term safety of varenicline for smoking cessation Williams KE Reeves KR Billing CB Jr Pennington AM Gong J Curr Med Res Opin 2007 23 793 801 10.1185/030079907X182185 17407636 A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers Tsai ST Cho HJ Cheng HS Kim CH Hsueh KC Billing CB Jr Williams KE Clin Ther 2007 29 1027 1039 10.1016/j.clinthera.2007.06.011 17692719 Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers Nakamura M Oshima A Fujimoto Y Maruyama N Ishibashi T Reeves KR Clin Ther 2007 29 1040 1056 10.1016/j.clinthera.2007.06.012 17692720 Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers Burstein AH Fullerton T Clark DJ Faessel HM J Clin Pharmacol 2006 46 1234 1240 10.1177/0091270006291837 17050788 Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation Oncken C Gonzales D Nides M Rennard S Watsky E Billing CB Anziano R Reeves K Arch Intern Med 2006 166 1571 1577 10.1001/archinte.166.15.1571 16908789 Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial Tonstad S Tonnesen P Hajek P Williams KE Billing CB Reeves KR Jama 2006 296 64 71 10.1001/jama.296.1.64 16820548 Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist Tonstad S J Cardiovasc Nurs 2006 21 433 436 17293731 Post-myocardial infarction smoking cessation counseling: associations with immediate and late mortality in older Medicare patients Houston TK Allison JJ Person S Kovac S Williams OD Kiefe CI Am J Med 2005 118 269 275 10.1016/j.amjmed.2004.12.007 15745725 Prevention of relapse after quitting smoking: a systematic review of trials Lancaster T Hajek P Stead LF West R Jarvis MJ Arch Intern Med 2006 166 828 835 10.1001/archinte.166.8.828 16636207 Evaluation of networks of randomized trials Salanti G Higgins JP Ades AE Ioannidis JP Stat Methods Med Res 2008 17 279 301 10.1177/0962280207080643 17925316 The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials Bucher HC Guyatt GH Griffith LE Walter SD J Clin Epidemiol 1997 50 683 691 10.1016/S0895-4356(97)00049-8 9250266 Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments A Network Meta-Analysis Involving More Than 65,000 Patients Mills EJ Wu P Rachlis B Arora P Deveraux PJ Perri D JACC 2008 52 1769 1781 19022156